Centaurus Financial, Inc. Revance Therapeutics, Inc. Transaction History

Centaurus Financial, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	SELL	$5.81 - $11.2 $40,176 - $77,448	-6,915 Reduced 28.19%	17,612 $154,000
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $83,065 - $181,556	7,242 Added 41.9%	24,527 $281,000
Q2 2023 Aug 15, 2023	BUY	$24.7 - $37.61 $34,678 - $52,804	1,404 Added 8.84%	17,285 $437,000
Q1 2023 May 17, 2023	BUY	$18.36 - $35.27 $12,631 - $24,265	688 Added 4.53%	15,881 $512,000
Q4 2022 Feb 10, 2023	SELL	$18.32 - $30.66 $22,295 - $37,313	-1,217 Reduced 7.42%	15,193 $280,000
Q3 2022 Dec 05, 2022	SELL	$14.33 - $28.47 $54,998 - $109,267	-3,838 Reduced 18.95%	16,410 $443,000
Q2 2022 Aug 02, 2022	SELL	$11.52 - $20.4 $5,091 - $9,016	-442 Reduced 2.14%	20,248 $280,000
Q1 2022 May 13, 2022	SELL	$12.36 - $20.31 $2,323 - $3,818	-188 Reduced 0.9%	20,690 $403,000
Q4 2021 Feb 01, 2022	SELL	$12.46 - $27.87 $378,061 - $845,631	-30,342 Reduced 59.24%	20,878 $341,000
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $36,169 - $46,593	1,403 Added 2.82%	51,220 $1.43 Million
Q2 2021 Aug 10, 2021	SELL	$26.8 - $31.84 $20,368 - $24,198	-760 Reduced 1.5%	49,817 $1.48 Million
Q1 2021 Apr 30, 2021	SELL	$24.03 - $29.97 $78,385 - $97,762	-3,262 Reduced 6.06%	50,577 $1.41 Million
Q4 2020 Jan 25, 2021	SELL	$23.41 - $28.34 $165,625 - $200,505	-7,075 Reduced 11.61%	53,839 $1.53 Million
Q3 2020 Nov 12, 2020	BUY	$23.23 - $34.3 $1.42 Million - $2.09 Million	60,914 New	60,914 $1.53 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.